Than Semaglutide Reduction FDA Approval Triple agonism is not just an incremental improvement
Several pathologies that affect the brain and kidneys have been associated with dysbiosis of the gut microbiota, and compared to the general population, individuals with CKD have a higher propensity for cognitive impairment (Drew et al., 2019)
Concurrently, the glucose-lowering strategy has evolved from solely managing hyperglycemia to emphasizing comprehensive, long-term patient benefits
Novo scientists are still mining the data for insights about the drugs effects
Oral administration is the preferred route, but challenges such as poor gastrointestinal stability, large molecular weight, and difficulty crossing the intestinal epithelium limit the development of oral peptide formulations
GLP-1 receptor agonists are not recommended for everyone